The Irony of Humanization: Alemtuzumab, the First, But One of the Most Immunogenic, Humanized Monoclonal Antibodies

Alemtuzumab was designed to reduce the immunogenicity of the parent CD52-specific rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relapsing multiple sclerosis (Lemtrada®). Perhaps due to its histo...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, David, Ali, Liaqat, Saxena, Gauri, Pryce, Gareth, Jones, Meleri, Schmierer, Klaus, Giovannoni, Gavin, Gnanapavan, Sharmilee, Munger, Kathleen C., Samkoff, Lawrence, Goodman, Andrew, Kang, Angray S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034358/
https://www.ncbi.nlm.nih.gov/pubmed/32117274
http://dx.doi.org/10.3389/fimmu.2020.00124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7034358/
https://www.ncbi.nlm.nih.gov/pubmed/32117274
http://dx.doi.org/10.3389/fimmu.2020.00124

Ejemplares similares